Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing

For oncology drugs that were approved by the US Food and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the use of enrichment (biomarker-positive patients) and a randomized controlled design by pre-approval trials and 2) the treatment-by-biomarker interactio...

Descripción completa

Detalles Bibliográficos
Autores principales: Vivot, Alexandre, Boutron, Isabelle, Béraud-Chaulet, Geoffroy, Zeitoun, Jean-David, Ravaud, Philippe, Porcher, Raphaël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537292/
https://www.ncbi.nlm.nih.gov/pubmed/28761069
http://dx.doi.org/10.1038/s41598-017-07358-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537292/
https://www.ncbi.nlm.nih.gov/pubmed/28761069
http://dx.doi.org/10.1038/s41598-017-07358-7

Ejemplares similares